Related Experiment Videos
Hemodialysis vascular access dysfunction from basic biology to clinical intervention
Prabir Roy-Chaudhury1, Burnett S Kelly, Ashwath Narayana
1University of Cincinnati Medical Center, Cincinnati, OH, USA.
Insights
Venous neointimal hyperplasia causes hemodialysis vascular access dysfunction, leading to hospitalization and high costs. Understanding its pathogenesis is key to developing effective local therapies for this condition.
Area of Science:
- Vascular Biology
- Nephrology
- Surgical Innovation
Background:
- Hemodialysis vascular access dysfunction is a significant clinical problem, causing morbidity and costing over $1 billion annually.
- Venous stenosis and thrombosis, driven by venous neointimal hyperplasia, are primary causes of access failure.
- Current therapeutic options for this condition are limited due to an incomplete understanding of its underlying mechanisms.
Purpose of the Study:
- To review the histological characteristics of venous neointimal hyperplasia in human and animal models.
- To identify potential therapeutic targets within the neointimal hyperplasia lesion.
- To propose polytetrafluoroethylene (PTFE) dialysis grafts as a model for testing novel local therapies.
Main Methods:
- Histological examination of human venous neointimal hyperplasia specimens.
- Analysis of a pig model exhibiting similar pathological features.
- Review of existing literature on the pathogenesis and potential treatments.
Main Results:
- Venous neointimal hyperplasia is characterized by smooth muscle cell proliferation, angiogenesis, and extracellular matrix accumulation.
- These cellular and matrix components represent potential targets for therapeutic intervention.
- The pig model effectively recapitulates key features of human venous neointimal hyperplasia.
Conclusions:
- A deeper understanding of venous neointimal hyperplasia pathogenesis is crucial for developing effective treatments.
- Polytetrafluoroethylene grafts offer a viable clinical model for evaluating localized therapies.
- Future research should focus on targeting specific cellular and molecular pathways involved in neointimal hyperplasia.
Abstract:
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population at a cost of over 1 billion dollars per annum. Venous stenosis and thrombosis as a result of venous neointimal hyperplasia are the major causes of hemodialysis vascular access dysfunction. Despite the magnitude of the clinical problem, there are currently no effective therapies for this condition. We believe that this could be because of an inadequate understanding of the pathogenesis of this condition. At a histological level, venous neointimal hyperplasia (both in human specimens and in a pig model) is characterized by the presence of smooth muscle cells/myofibroblasts, microvessel formation (angiogenesis), and the accumulation of extracellular matrix components, all of which could be potential targets for therapeutic intervention. In particular, polytetrafluoroethylene dialysis access grafts could be the ideal clinical model for testing out novel local therapies to block neointimal hyperplasia. The current review describes the lesion of venous neointimal hyperplasia in human samples and in a pig model and suggests possible future directions for the development of effective local therapies for this condition.